16.32
-0.73%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ryvu Therapeutics
Its shares trade on GPW under the ticker RVU.WA. It has been listed since 14 July 2011. In the fiscal year to 31 December 2025, it reported revenue of PLN 62.3m and a net loss of PLN 101.2m. At that date it held total assets of PLN 224.4m and shareholders' equity of PLN 53.8m.
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 14 Jul 2011
- Employees
- 158
- Website
- ryvu.com ↗
Leadership
Pay as last reported
- Dr. Piotr RomanowskiIndependent Chairman of the Supervisory Board, since 2010PLN 150,477
- Dr. Tadeusz WesolowskiVice Chairman of the Supervisory Board, since 2011PLN 148,255
- Dr. Krzysztof BrzozkaVice President of the Management Board, Chief Scientific OfficerPLN 595,507
- Dr. Kamil SitarzChief Operating Officer, Member of the Management BoardPLN 485,541
- Mr. Vatnak Vat-hoChief Business Officer, Member of the Management BoardPLN 937,984
- Mr. Rafal ChwastIndependent Member of the Supervisory BoardPLN 150,477
- Dr. Scott FieldsMember of the Supervisory Board
- Mr. Axel GlasmacherMember of the Supervisory BoardPLN 148,255
- Dr. Peter SmithMember of the Supervisory Board
- Mr. Thomas TuralskiMember of the Supervisory BoardPLN 148,255
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ryvu Therapeutics SA has a strong portfolio of innovative therapies and drugs.
- The company has a highly skilled and experienced management team.
- Ryvu Therapeutics SA has established partnerships with renowned research institutions.
Weaknesses
- The company is dependent on the success of its drug development pipeline.
- Ryvu Therapeutics SA is a relatively small player in the pharmaceutical industry.
- The company may face challenges in securing sufficient funding for its research and development activities.
Opportunities
- There is a growing demand for effective and personalized treatments in the healthcare market.
- Ryvu Therapeutics SA can leverage advancements in technology to enhance its drug discovery process.
- The company can explore expansion into new geographical markets.
Threats
- The pharmaceutical industry is highly competitive and subject to stringent regulatory requirements.
- Ryvu Therapeutics SA may face challenges in obtaining intellectual property protection for its innovations.
- Unexpected clinical trial outcomes or failures could negatively impact the company's reputation and financial stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.